超声造影定量分析评价肿瘤血管靶向药物Ⅰ期临床试验疗效  

Quantitative analysis of curative effect of the tumor targeted agent in phase Ⅰ trial with contrast enhanced ultrasound

作　　者：刘隆忠[1] 裴小青[1] 曾永霞[1] 郑玮[1] 李安华[1] 

机构地区：[1]华南肿瘤学国家重点实验室中山大学肿瘤防治中心超声科,广东广州510060

出　　处：《中国医学影像技术》2011年第10期2067-2070,共4页Chinese Journal of Medical Imaging Technology

摘　　要：目的观察CEUS定量分析在肿瘤血管靶向药物M2ESⅠ期临床试验疗效评估中的应用价值,分析定量灌注参数与实体瘤疗效评价标准(RECIST标准)的相关性。方法对15例肝转移癌患者,分别按不同给药剂量(15、30、45、60 mg/m2)每周给药1次,共3次。对每例患者于治疗前及给药后第2、7、9、14、16、21天分别行常规超声及CEUS检查。使用SonoTumor定量分析软件计算各功能参数。疗效评估采用RECIST标准。结果与无效组比较,有效组CEUS定量分析的流入相曲线下面积及峰值强度在治疗后第2、9天明显减低(P<0.05),但在第7、14天恢复至治疗前水平。结论在肿瘤血管靶向药物Ⅰ期临床试验中,CEUS定量分析能够早期评价用药后肿瘤的血流灌注变化。Objective To evaluate the early effects of a tumor targeted agent M2ES in phase Ⅰ trial in the patients with metastatic liver cancer using quantitative analysis of CEUS,and to investigate the correlation between response evaluation criteria in solid tumors（RECIST） and tumor perfusion parameters.Methods Fifteen patients with metastatic liver cancer were enrolled in this study.M2ES was administrated 15,30,45,60 mg/m2 once a week for three weeks,respectively.CEUS was performed before treatment and on the 2nd,7th,9th,14th,16th,and 21st days after treatment,quantitative analysis was performed using SonoTumor software.All patients were rated as responders or nonresponders according to RECIST.Results The percentage changes in several parameters including peak enhancement and wash-in area under curve revealed decrease at the 2nd and the 9th day,showing correlation with RECIST response（P0.05）,but returned to the lever of pretherapy on the 7th and 14th days.Conclusion CEUS allows the early quantitative evaluation of tumor perfusion for M2ES in phase Ⅰ trial of the patients with metastatic liver cancer.

关 键 词：肝肿瘤 肿瘤转移 超声检查 介入性 

分 类 号：R730.3[医药卫生—肿瘤] R445.1[医药卫生—临床医学]